In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Zomedica Corp’s stock clocked out at $0.14, down -6.69% from its previous closing price of $0.15. In other words, the price has decreased by -$6.69 from its previous closing price. On the day, 6.93 million shares were traded. ZOM stock price reached its highest trading level at $0.1494 during the session, while it also had its lowest trading level at $0.136.
Ratios:
To gain a deeper understanding of ZOM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.15 and its Current Ratio is at 10.82. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Dawson James on January 06, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 08 ’24 when Blair Anthony K bought 150,000 shares for $0.12 per share. The transaction valued at 18,450 led to the insider holds 400,000 shares of the business.
POWERS JOHNNY D bought 100,000 shares of ZOM for $12,100 on Nov 11 ’24. The Director now owns 2,425,000 shares after completing the transaction at $0.12 per share. On Nov 11 ’24, another insider, HEATON LARRY C II, who serves as the CEO of the company, bought 100,000 shares for $0.12 each. As a result, the insider paid 12,200 and bolstered with 500,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZOM now has a Market Capitalization of 135233104 and an Enterprise Value of 42043876. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.06 while its Price-to-Book (P/B) ratio in mrq is 0.67. Its current Enterprise Value per Revenue stands at 1.612 whereas that against EBITDA is -1.43.
Stock Price History:
Over the past 52 weeks, ZOM has reached a high of $0.23, while it has fallen to a 52-week low of $0.12. The 50-Day Moving Average of the stock is 7.95%, while the 200-Day Moving Average is calculated to be -1.19%.
Shares Statistics:
It appears that ZOM traded 4.48M shares on average per day over the past three months and 9572440 shares per day over the past ten days. A total of 979.95M shares are outstanding, with a floating share count of 962.81M. Insiders hold about 1.75% of the company’s shares, while institutions hold 8.33% stake in the company. Shares short for ZOM as of 1728950400 were 51140313 with a Short Ratio of 11.75, compared to 1726185600 on 43371169. Therefore, it implies a Short% of Shares Outstanding of 51140313 and a Short% of Float of 5.21.
Earnings Estimates
Investors are keenly observing as 1 analysts analyze and rate the current performance of Zomedica Corp (ZOM) in the stock market.The consensus estimate for the next quarter is -$0.01, with high estimates of -$0.01 and low estimates of -$0.01.
Analysts are recommending an EPS of between -$0.03 and -$0.03 for the fiscal current year, implying an average EPS of -$0.03. EPS for the following year is -$0.03, with 1.0 analysts recommending between -$0.03 and -$0.03.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $7.78M. There is a high estimate of $7.78M for the next quarter, whereas the lowest estimate is $7.78M.
Based on 1 analysts’ estimates, the company’s revenue will be $35.16M in the next fiscal year. The high estimate is $35.16M and the low estimate is $35.16M.
